Correlation Between Okta and Lipella Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Okta and Lipella Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Okta and Lipella Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Okta Inc and Lipella Pharmaceuticals Common, you can compare the effects of market volatilities on Okta and Lipella Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Okta with a short position of Lipella Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Okta and Lipella Pharmaceuticals.
Diversification Opportunities for Okta and Lipella Pharmaceuticals
0.14 | Correlation Coefficient |
Average diversification
The 3 months correlation between Okta and Lipella is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Okta Inc and Lipella Pharmaceuticals Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipella Pharmaceuticals and Okta is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Okta Inc are associated (or correlated) with Lipella Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipella Pharmaceuticals has no effect on the direction of Okta i.e., Okta and Lipella Pharmaceuticals go up and down completely randomly.
Pair Corralation between Okta and Lipella Pharmaceuticals
Given the investment horizon of 90 days Okta Inc is expected to generate 0.27 times more return on investment than Lipella Pharmaceuticals. However, Okta Inc is 3.7 times less risky than Lipella Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Lipella Pharmaceuticals Common is currently generating about -0.01 per unit of risk. If you would invest 7,250 in Okta Inc on August 29, 2024 and sell it today you would earn a total of 433.00 from holding Okta Inc or generate 5.97% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Okta Inc vs. Lipella Pharmaceuticals Common
Performance |
| Timeline |
| Okta Inc |
| Lipella Pharmaceuticals |
Okta and Lipella Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Okta and Lipella Pharmaceuticals
The main advantage of trading using opposite Okta and Lipella Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Okta position performs unexpectedly, Lipella Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will offset losses from the drop in Lipella Pharmaceuticals' long position.The idea behind Okta Inc and Lipella Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Lipella Pharmaceuticals vs. Senti Biosciences | Lipella Pharmaceuticals vs. Fennec Pharmaceuticals | Lipella Pharmaceuticals vs. Monopar Therapeutics | Lipella Pharmaceuticals vs. Akeso, Inc |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Complementary Tools
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |